191 related articles for article (PubMed ID: 33669315)
1. Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models.
Kim E; Brown JS; Eroglu Z; Anderson ARA
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669315
[TBL] [Abstract][Full Text] [Related]
2. Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma.
Smalley I; Kim E; Li J; Spence P; Wyatt CJ; Eroglu Z; Sondak VK; Messina JL; Babacan NA; Maria-Engler SS; De Armas L; Williams SL; Gatenby RA; Chen YA; Anderson ARA; Smalley KSM
EBioMedicine; 2019 Oct; 48():178-190. PubMed ID: 31594749
[TBL] [Abstract][Full Text] [Related]
3. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.
West J; Adler F; Gallaher J; Strobl M; Brady-Nicholls R; Brown J; Roberson-Tessi M; Kim E; Noble R; Viossat Y; Basanta D; Anderson ARA
Elife; 2023 Mar; 12():. PubMed ID: 36952376
[TBL] [Abstract][Full Text] [Related]
4. The impact of the spatial heterogeneity of resistant cells and fibroblasts on treatment response.
M A M; Kim JY; Pan CH; Kim E
PLoS Comput Biol; 2022 Mar; 18(3):e1009919. PubMed ID: 35263336
[TBL] [Abstract][Full Text] [Related]
5. Effective dose window for containing tumor burden under tolerable level.
Masud MA; Kim JY; Kim E
NPJ Syst Biol Appl; 2023 May; 9(1):17. PubMed ID: 37221258
[TBL] [Abstract][Full Text] [Related]
6. Range-Bounded Adaptive Therapy in Metastatic Prostate Cancer.
Brady-Nicholls R; Enderling H
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358738
[TBL] [Abstract][Full Text] [Related]
7. Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics.
Brady-Nicholls R; Zhang J; Zhang T; Wang AZ; Butler R; Gatenby RA; Enderling H
Neoplasia; 2021 Sep; 23(9):851-858. PubMed ID: 34298234
[TBL] [Abstract][Full Text] [Related]
8. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics.
Gallaher J; Strobl M; West J; Gatenby R; Zhang J; Robertson-Tessi M; Anderson ARA
Cancer Res; 2023 Aug; 83(16):2775-2789. PubMed ID: 37205789
[TBL] [Abstract][Full Text] [Related]
9. Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm.
Tsur N; Kogan Y; Avizov-Khodak E; Vaeth D; Vogler N; Utikal J; Lotem M; Agur Z
J Transl Med; 2019 Oct; 17(1):338. PubMed ID: 31590677
[TBL] [Abstract][Full Text] [Related]
10. Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity.
Aguadé-Gorgorió G; Kauffman S; Solé R
Bull Math Biol; 2021 Dec; 84(1):24. PubMed ID: 34958403
[TBL] [Abstract][Full Text] [Related]
11. Budget Impact of Adaptive Abiraterone Therapy for Castration-Resistant Prostate Cancer.
Mason NT; Burkett JM; Nelson RS; Pow-Sang JM; Gatenby RA; Kubal T; Peabody JW; Letson GD; McLeod HL; Zhang J
Am Health Drug Benefits; 2021 Mar; 14(1):15-20. PubMed ID: 33841621
[TBL] [Abstract][Full Text] [Related]
12. Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.
Kim E; Rebecca VW; Smalley KS; Anderson AR
Eur J Cancer; 2016 Nov; 67():213-222. PubMed ID: 27689717
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. Computational Model of Heterogeneity in Melanoma: Designing Therapies and Predicting Outcomes.
Hodgkinson A; Trucu D; Lacroix M; Le Cam L; Radulescu O
Front Oncol; 2022; 12():857572. PubMed ID: 35494017
[TBL] [Abstract][Full Text] [Related]
15. Optimizing Adaptive Therapy Based on the Reachability to Tumor Resistant Subpopulation.
Wang J; Zhang Y; Liu X; Liu H
Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771426
[TBL] [Abstract][Full Text] [Related]
16. Towards Multidrug Adaptive Therapy.
West J; You L; Zhang J; Gatenby RA; Brown JS; Newton PK; Anderson ARA
Cancer Res; 2020 Apr; 80(7):1578-1589. PubMed ID: 31948939
[TBL] [Abstract][Full Text] [Related]
17. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes.
Zhang J; Cunningham J; Brown J; Gatenby R
Elife; 2022 Jun; 11():. PubMed ID: 35762577
[TBL] [Abstract][Full Text] [Related]
18. In Silico Investigations of Multi-Drug Adaptive Therapy Protocols.
Thomas DS; Cisneros LH; Anderson ARA; Maley CC
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681680
[TBL] [Abstract][Full Text] [Related]
19. Modeling the effect of acquired resistance on cancer therapy outcomes.
Masud MA; Kim JY; Kim E
Comput Biol Med; 2023 Aug; 162():107035. PubMed ID: 37276754
[TBL] [Abstract][Full Text] [Related]
20. Modifying Adaptive Therapy to Enhance Competitive Suppression.
Hansen E; Read AF
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
